Published online Sep 27, 2022. doi: 10.4254/wjh.v14.i9.1778
Peer-review started: January 12, 2022
First decision: April 16, 2022
Revised: April 30, 2022
Accepted: August 22, 2022
Article in press: August 22, 2022
Published online: September 27, 2022
No prognostic models specific to hepatocellular carcinoma patients receiving surgical resection have been considered strong and convincing enough for surv
To simplify our score and compare research outcomes among other scoring systems.
We retrospectively reviewed data from 1106 patients with hepatocellular carc
Among the 1106 patients, 731 (66.1%) had tumor recurrence at a median follow-up of 83.9 mo. Five risk factors were identified: platelet count, albumin level, indocyanine green retention rate, multiplicity, and radiologic total tumor volume. Patients were divided into three risk groups, and the 5-year survival rates were 61.7%, 39%, and 25.7%, respectively. The C-index was 0.617, which was higher than the Tokyo score (0.613) and the Taipei Integrated Scoring System (0.562) and equal to the value of the AJCC 8th edition (0.617).
The modified score provides an easier method to predict survival. Appropriate treatment can be planned preoperatively by dividing patients into risk groups.
Core Tip: This retrospective study recruited over 1000 patients and developed a simple preoperative score to evaluate the recurrence risk of hepatocellular carcinoma after surgical resection. Despite the lack of pathological features, predictive power was satisfactory. Appropriate treatment can be planned preoperatively by dividing patients into risk groups.